184:
291:
34:
27:
322:
255:
170:= "The particular advantage of this drug is the low incidence of troublesome side effects (25)." "Side effects were usually trivial (26)."
317:
87:
312:
307:
48:
239:
Estrogen Action, Selective
Estrogen Receptor Modulators And Women's Health: Progress And Promise
206:
251:
237:
218:
73:
243:
160:
301:
44:
138:
247:
236:
Howell A, Jordan VC (2013). "Adjuvant
Antihormone Therapy". In Craig JV (ed.).
134:
116:
145:
94:
222:
178:
130:
109:
284:
276:
272:
207:"The estrogen receptor: a model for molecular medicine"
269:Editors can experiment in this template's sandbox
43:Comparison of early clinical experience with
28:
8:
35:
21:
323:Templates that generate named references
15:
197:
242:. World Scientific. pp. 229–254.
16:
7:
205:Jensen EV, Jordan VC (June 2003).
14:
182:
1:
339:
268:
248:10.1142/9781848169586_0010
292:Subpages of this template
166:
88:Acute psychotic episodes
187:Template documentation
49:advanced breast cancer
318:Medication templates
52:
257:978-1-84816-959-3
177:
176:
78:500–4,500 mg/day
74:Ethamoxytriphetol
330:
288:
280:
262:
261:
233:
227:
226:
211:Clin. Cancer Res
202:
188:
186:
185:
161:thrombocytopenia
68:Adverse effects
53:
51:
37:
30:
23:
338:
337:
333:
332:
331:
329:
328:
327:
298:
297:
296:
295:
290:
282:
270:
267:
266:
265:
258:
235:
234:
230:
204:
203:
199:
194:
189:
183:
181:
121:180–240 mg/day
99:100–300 mg/day
42:
41:
12:
11:
5:
336:
334:
326:
325:
320:
315:
310:
300:
299:
281:and testcases
264:
263:
256:
228:
196:
195:
193:
190:
180:
179:
175:
174:
164:
163:
157:
154:
151:
148:
142:
141:
128:
125:
122:
119:
113:
112:
106:
103:
100:
97:
91:
90:
85:
82:
79:
76:
70:
69:
66:
65:Response rate
63:
60:
57:
40:
39:
32:
25:
17:
13:
10:
9:
6:
4:
3:
2:
335:
324:
321:
319:
316:
314:
313:Breast cancer
311:
309:
308:Antiestrogens
306:
305:
303:
293:
286:
278:
274:
259:
253:
249:
245:
241:
240:
232:
229:
224:
220:
217:(6): 1980–9.
216:
212:
208:
201:
198:
191:
173:
169:
165:
162:
158:
155:
152:
150:20–40 mg/day
149:
147:
144:
143:
140:
136:
132:
129:
126:
123:
120:
118:
115:
114:
111:
107:
104:
101:
98:
96:
93:
92:
89:
86:
83:
80:
77:
75:
72:
71:
67:
64:
61:
58:
56:Antiestrogen
55:
54:
50:
46:
45:antiestrogens
38:
33:
31:
26:
24:
19:
18:
238:
231:
214:
210:
200:
171:
167:
20:
139:photophobia
302:Categories
192:References
168:Footnotes:
159:Transient
153:1971–1973
135:ichthyosis
117:Nafoxidine
102:1964–1974
146:Tamoxifen
131:Cataracts
110:cataracts
108:Risks of
95:Clomifene
223:12796359
172:Sources:
62:Year(s)
275:|
59:Dosage
289:pages.
285:create
277:mirror
273:create
254:
221:
124:1976
81:1960
252:ISBN
219:PMID
156:31%
127:31%
105:34%
84:25%
47:for
244:doi
304::
250:.
213:.
209:.
137:,
133:,
294:.
287:)
283:(
279:)
271:(
260:.
246::
225:.
215:9
36:e
29:t
22:v
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.